Agenda

9:00 - 11:00 AM

11:00 - 11: 40 AM

11:40 - 11:50 AM

12:00 - 1:30 PM

1:45 - 2:00 PM

2:00 - 2:20 PM

I2I Pitch Competition at the Feinstein’s Hotel Nikko - (Reservation Required) 

Re-Imagine Toxicity and Reducing Drug Manufacturing costs: A call to action to VCs

I2I Closing Remarks (Results Announced Saturday)

Luncheon (Reservation Required) 

Conference Opening - Welcome: Where we have been, what we know, what we don't, and opportunities for intervention: Accelerating learning in prevention, our approach to hormonal interventions 

Keynote: How do we do something revolutionary that has never been done before?

2:20 - 3:10 PM

Panel Discussion: A big vision for primary and secondary prevention 

3:20 - 4:50 PM

4:50 - 5:50 PM

Session 1: Rethinking our screening approach: An overview of Personalized Screening and other Risk Assessment Trials (WISDOM, MyPeBS)

Session 2: Impact from treatment to prevention: Translational Prevention Trials

6:00 - 7:30 PM

Poster Session 1 & Appetizers

8:00 - 9:00 AM

Session 3: Overcoming resistance from the ground up: What are the drivers, and how can they inform our prevention approach?

9:00 - 9:15 AM

I2I 2024 Winner Talk: “A potential for both treatment-resistant tumors and prevention? Control of the estrogenic stimulation of the breast via the ubiquitous androgen receptor pathway” 

• Stephen Birrell, MD, PhD, FRACS, Dame Roma Mitchell Cancer Research Laboratories 

• Wayne Tilley, PhD, Dame Roma Mitchell Cancer Research Laboratories 

9:15 - 10:30 AM

11:00 - 12:00 PM

Session 4: Early Imaging Endpoints to Accelerate the Learning Cycle (Risk Assessment and Response)

Session 5: Early Endpoints (Tissue/Blood/Saliva/path AI-based biomarkers) to Accelerate the Learning Cycle: biomarker candidates for both treatment response & prevention (benign disease, DCIS & EOP)

12:00 - 1:15 PM

1:15 - 2:30 PM

2:30 - 3:30 PM

Poster Session 2 (Lunch Included)

Session 6:  Dobbs Decision & the series of new state laws: Impact on Women 

Session 7:  DEI as fundamental to personalized medicine: best techniques to trial promote enrollment across all groups 

3:45 - 5:00 PM

5:00 - 7:00 PM

Session 8: Tissue and imaging combinations that elucidate a new way to think about treatment and prevention: Postpartum Breast Cancer

Conference Dinner that promotes conversation & discussion: A meeting of the minds

8:00 - 9:00 AM

Poster Session 3

9:00 - 10:30 AM

Session 9: Environment, the Exposome & Inflammation as a Mediator of Breast Cancer Risk

10:30 - 11:30 AM

Session 10: How do we reduce the risk of developing obesity or metabolic syndrome?

11:30 - 12:30 PM

I2I 2024 Winner Talk: “Innovative Fitness Solutions for Health Equity in Cancer Care”

• Jennifer Johnson, JennJHealth

12:30 - 1:00 PM

Lunch 

1:00 - 2:00 PM

2:00 - 2:15 PM

Session 11: Treating Obesity / Obesity in the Context of the Larger Hormonal Picture 

I2I 2024 Winner Talk: “Biomarker of tirzepatide effectiveness for cancer”

• Erin Giles, PhD, University of Michigan

2:15 - 3:15 PM

Session 12:  Rethinking Contraceptives: current risk for breast cancer and potential future combinations

3:15 - 3:30 PM

I2I 2024 Winner Talk: "Novel breast cancer prevention strategies utilizing epigenetic markers and antiprogestins"

• Martin Widschwendter, MD, University College London

3:40 - 4:40 PM

4:40 - 5:40 PM

5:40 - 6:40 PM

Session 13: Postmenopausal hormone replacement therapy & alternatives in high-risk women without cancer: Balancing breast, brain, libido, hot flashes 

Session 14: Hormonal therapy & alternatives in women with cancer: Balancing breast, brain, libido, hot flashes 

Session 15: Can treatment of benign uterine conditions provide a path for breast cancer prevention? 

6:40 - 7:00 PM

I2I Awards Announced & Closing Remarks